7/30/2019 8:01:19 AM
Alkermes Announces Positive Topline Results From EVOLVE-MS-2 Phase 3 Study Of Diroximel Fumarate
7/29/2019 12:33:29 PM
Alkermes Announces Settlement With Amneal Over VIVITROL Patent Dispute
7/25/2019 7:02:31 AM
Alkermes Q2 Net Loss $42 Mln Or $0.27/shr Vs. Net Loss $32.6 Mln Or $0.21/shr Last Year
7/15/2019 7:02:58 AM
Alkermes Plans To Expand NDA For ALKS 3831 To Encompass Treatment Of Bipolar I Disorder In Addition To Schizophrenia
6/12/2019 7:02:21 AM
Alkermes Begins Monotherapy Expansion Stage Of ARTISTRY-1 Clinical Trial
5/13/2019 7:02:31 AM
Alkermes To Showcase Leadership In Schizophrenia With New Data Presentations At Upcoming Scientific Conferences
4/25/2019 7:02:05 AM
Alkermes Posts Q1 GAAP Net Loss Per Share Of $0.62 And Non-GAAP Net Loss Per Share Of $0.17
4/24/2019 4:02:01 PM
Alkermes Names Todd Nichols To Become SVP Of Sales And Marketing
4/9/2019 7:01:30 AM
Alkermes Announces Positive Topline Results From Innovative Study Of ARISTADA And INVEGA SUSTENNA For Schizophrenia
4/1/2019 7:02:40 AM
Alkermes To Present New ALKS 3831 Data From ENLIGHTEN-2 And Interim Extension Safety Study Results
2/26/2019 7:02:51 AM
Alkermes Initiates Clinical Study Of ALKS 4230 Administered Subcutaneously In Patients With Advanced Solid Tumors
2/25/2019 7:33:11 AM
Alkermes, Biogen Report FDA Acceptance Of Diroximel Fumarate New Drug Application For Multiple Sclerosis